<DOC>
	<DOC>NCT01609075</DOC>
	<brief_summary>This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Metastatic colorectal cancer Having initiated firstline treatment with fluoropyrimidinebased chemotherapy plus Avastin between 1. September 2011 and 29. February 2012 Availability of test fro KRAS genotyping Participation in a clinical trial during treatment with Avastin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>